On August 27, 2018 Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported an abstract from a study conducted in Germany of the use of the Delcath Hepatic CHEMOSAT Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for presentation as a poster at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting (Press release, Delcath Systems, AUG 27, 2018, View Source;p=RssLanding&cat=news&id=2364903 [SID1234529755]). The abstract, Survival and Response of Patients with Metastatic Ocular Melanoma after Chemosaturation Percutaneous Hepatic Perfusion, will be presented by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CIRSE 2018 annual meeting will be held in Lisbon, Portugal September 22-25, 2018.